The expression of mitochondrial transcription factor TFAM and Translocase Of Inner Mitochondrial Membrane 23 (TIMM23) reflect mitochondrial content and might therefore be indicative for response of HGSC to cisplatin based therapy, which still is the first-line therapy of ovarian cancer after surgery1,2. The gene discussed is TFAM; the disease is ovarian carcinoma.